Cargando…

Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China

OBJECTIVES: The performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin. METHODS: The MICs of 257 Gram-negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ying, Jia, Peiyao, Zhou, Menglan, Zhang, Jingjia, Zhang, Ge, Kang, Wei, Duan, Simeng, Wang, Tong, Xu, Yingchun, Yang, Qiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937900/
https://www.ncbi.nlm.nih.gov/pubmed/33692761
http://dx.doi.org/10.3389/fmicb.2020.610604
_version_ 1783661488392634368
author Zhu, Ying
Jia, Peiyao
Zhou, Menglan
Zhang, Jingjia
Zhang, Ge
Kang, Wei
Duan, Simeng
Wang, Tong
Xu, Yingchun
Yang, Qiwen
author_facet Zhu, Ying
Jia, Peiyao
Zhou, Menglan
Zhang, Jingjia
Zhang, Ge
Kang, Wei
Duan, Simeng
Wang, Tong
Xu, Yingchun
Yang, Qiwen
author_sort Zhu, Ying
collection PubMed
description OBJECTIVES: The performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin. METHODS: The MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2(®) COMPACT, Phoenix(TM) M50, and Bio-kont AST System were evaluated. Essential agreement (EA), category agreement (CA), very major error (VME), and major error (ME) were calculated for comparison. The results of mcr-1 positive strains were separately discussed. RESULTS: The EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for Pseudomonas spp. (EA, CA < 90%, VME > 1.5%, ME = 5.6%/10%) and Enterobacter spp. (EA, CA < 90%, VME > 1.5% and ME = 0%), Vitek to colistin for most genera, and Phoenix to colistin for Enterobacter spp. (EA, CA < 90%, VME > 1.5%, ME = 0%) were unsatisfactory compared with other genera. The performance of Bio-kont to polymyxins for Escherichia spp. and Phoenix to colistin for Citrobacter spp., Escherichia spp., and Klebsiella spp., which all met the CLSI standard, were satisfactory. When the susceptibility of mcr-1 positive E. coli was tested, Bio-kont and Phoenix M50 presented excellent performance with no category errors, while Vitek 2 performed a high VME (25.5%). CONCLUSION: With relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for Escherichia spp., Klebsiella spp., Citrobacter spp. and Acinetobacter spp.
format Online
Article
Text
id pubmed-7937900
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79379002021-03-09 Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China Zhu, Ying Jia, Peiyao Zhou, Menglan Zhang, Jingjia Zhang, Ge Kang, Wei Duan, Simeng Wang, Tong Xu, Yingchun Yang, Qiwen Front Microbiol Microbiology OBJECTIVES: The performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin. METHODS: The MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2(®) COMPACT, Phoenix(TM) M50, and Bio-kont AST System were evaluated. Essential agreement (EA), category agreement (CA), very major error (VME), and major error (ME) were calculated for comparison. The results of mcr-1 positive strains were separately discussed. RESULTS: The EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for Pseudomonas spp. (EA, CA < 90%, VME > 1.5%, ME = 5.6%/10%) and Enterobacter spp. (EA, CA < 90%, VME > 1.5% and ME = 0%), Vitek to colistin for most genera, and Phoenix to colistin for Enterobacter spp. (EA, CA < 90%, VME > 1.5%, ME = 0%) were unsatisfactory compared with other genera. The performance of Bio-kont to polymyxins for Escherichia spp. and Phoenix to colistin for Citrobacter spp., Escherichia spp., and Klebsiella spp., which all met the CLSI standard, were satisfactory. When the susceptibility of mcr-1 positive E. coli was tested, Bio-kont and Phoenix M50 presented excellent performance with no category errors, while Vitek 2 performed a high VME (25.5%). CONCLUSION: With relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for Escherichia spp., Klebsiella spp., Citrobacter spp. and Acinetobacter spp. Frontiers Media S.A. 2021-02-22 /pmc/articles/PMC7937900/ /pubmed/33692761 http://dx.doi.org/10.3389/fmicb.2020.610604 Text en Copyright © 2021 Zhu, Jia, Zhou, Zhang, Zhang, Kang, Duan, Wang, Xu and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Zhu, Ying
Jia, Peiyao
Zhou, Menglan
Zhang, Jingjia
Zhang, Ge
Kang, Wei
Duan, Simeng
Wang, Tong
Xu, Yingchun
Yang, Qiwen
Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_full Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_fullStr Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_full_unstemmed Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_short Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China
title_sort evaluation of the clinical systems for polymyxin susceptibility testing of clinical gram-negative bacteria in china
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937900/
https://www.ncbi.nlm.nih.gov/pubmed/33692761
http://dx.doi.org/10.3389/fmicb.2020.610604
work_keys_str_mv AT zhuying evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT jiapeiyao evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT zhoumenglan evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT zhangjingjia evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT zhangge evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT kangwei evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT duansimeng evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT wangtong evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT xuyingchun evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina
AT yangqiwen evaluationoftheclinicalsystemsforpolymyxinsusceptibilitytestingofclinicalgramnegativebacteriainchina